"It's exciting that these diabetes medications may offer additional benefits, such as protecting brain health. As the use of GLP-1 receptor agonists (GLP-1RAs) continues to expand, it becomes increasingly important to understand their real-world benefits and risks across diverse populations."
"This research represents a significant contribution to our understanding of how glucose-lowering medications may impact brain health. Diabetes is a known risk factor for dementia, but whether glucose-lowering therapies can help prevent cognitive decline has been unclear."
Recent studies suggest that GLP-1 drugs, including Ozempic, may lower the risk of developing dementia, particularly in individuals with type 2 diabetes. Research published in JAMA Neurology identified a strong association between these diabetes medications and a reduced incidence of Alzheimer's disease. The studies examined various glucose-lowering therapies and found meaningful benefits in brain health. As diabetes is a known risk factor for dementia, this research may broaden the therapeutic applications of GLP-1 receptor agonists, emphasizing the importance of understanding these drugs' overall impact on brain health in diverse populations.
Read at New York Post
Unable to calculate read time
Collection
[
|
...
]